Multiple endocrine neoplasia type 1 other imaging findings

Jump to navigation Jump to search

Multiple endocrine neoplasia type 1 Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Multiple endocrine neoplasia type 1 from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Multiple endocrine neoplasia type 1 other imaging findings On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Multiple endocrine neoplasia type 1 other imaging findings

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Multiple endocrine neoplasia type 1 other imaging findings

CDC on Multiple endocrine neoplasia type 1 other imaging findings

Multiple endocrine neoplasia type 1 other imaging findings in the news

Blogs on Multiple endocrine neoplasia type 1 other imaging findings

Directions to Hospitals Treating Multiple endocrine neoplasia type 1

Risk calculators and risk factors for Multiple endocrine neoplasia type 1 other imaging findings

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [2]

Overview

Other imaging studies for multiple endocrine neoplasia type 1 include fluoro-di-glucose-PET/CT, venous sampling, angiography and endovascular procedures, such as trans-arterial chemo-embolization (TACE).

Other imaging findings

Nuclear Medicine

  • Common radiopharmaceutical agent is 111-indium-pentetreotide, which is a ligand for somatostatin receptor on the cell membrane of many neuroendocrine tumors. Multiple tumor sites and metastasis can be identified using a gamma-camera which detect the emitted radiation.
  • Can be used in combination with cross-sectional imaging modalities to aid staging e.g. SPECT or PET-CT or PET-MRI. [1] [1]
  • Can be used to predict response to nuclear medicine based therapies, and, in some cases, to assess response to treatment
  • Care should be taken with interpretation of images as drugs can interfere with somatostain receptor expression, e.g. interferon.
  • Neuroendocrine tumors can differentiate into tumors that do not express somatostatin receptors can become ‘image negative’ making reoccurrence or metastases more challenging to detect. Other radiopharmaceuticals are also used, based on certain physiological characteristics e.g. cell surface receptors or uptake of molecules.
  • Gallium-68 labelled somatostatin analogues (PET/CT) is thought to be more sensitive in detecting neuroendocrine tumors except pulmonary and hepatic metastases. For aggressive, rapidly growing tumors (i.e. high metabolism) fluoro-di-glucose-PET/CT can be used (FDG-PET). [2] [3] [4] [5]
  • F18 DOPA and C11 Hydroxytryptophan may be used in future but are not routinely available.

Invasive Imaging Techniques

  • Venous sampling can be used in small functional neuroendocrine tumors where cross sec-tional imaging is equivocal.
  • Multiple endocrine neoplasia type 1 can present with multiple lesions. Functional neuroendocrine tumors can be identified from these, using calcium stimulation with venous sampling.

References

  1. 1.0 1.1 Park HL, Yoo IR, Kim SH, Lee S (2016). "Multiple endocrine neoplasia type 1 with anterior mediastinal parathyroid adenoma: successful localization using Tc-99m sestamibi SPECT/CT". Ann Surg Treat Res. 91 (6): 323–326. doi:10.4174/astr.2016.91.6.323. PMC 5128379. PMID 27904855.
  2. Lastoria S, Marciello F, Faggiano A, Aloj L, Caracò C, Aurilio M; et al. (2016). "Role of (68)Ga-DOTATATE PET/CT in patients with multiple endocrine neoplasia type 1 (MEN1)". Endocrine. 52 (3): 488–94. doi:10.1007/s12020-015-0702-y. PMID 26242621.
  3. Sadowski SM, Millo C, Cottle-Delisle C, Merkel R, Yang LA, Herscovitch P; et al. (2015). "Results of (68)Gallium-DOTATATE PET/CT Scanning in Patients with Multiple Endocrine Neoplasia Type 1". J Am Coll Surg. 221 (2): 509–17. doi:10.1016/j.jamcollsurg.2015.04.005. PMC 4515773. PMID 26206648.
  4. Albers MB, Librizzi D, Lopez CL, Manoharan J, Apitzsch JC, Slater EP; et al. (2017). "Limited Value of Ga-68-DOTATOC-PET-CT in Routine Screening of Patients with Multiple Endocrine Neoplasia Type 1". World J Surg. 41 (6): 1521–1527. doi:10.1007/s00268-017-3907-9. PMID 28138732.
  5. Goroshi M, Bandgar T, Lila AR, Jadhav SS, Khare S, Shrikhande SV; et al. (2016). "Multiple endocrine neoplasia type 1 syndrome: single centre experience from western India". Fam Cancer. 15 (4): 617–24. doi:10.1007/s10689-016-9891-7. PMID 26905068.

Template:WS Template:WH